BCDA
BioCardia, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.06
−2.75%Aug 24, 2026, 12:30 UTC
BioCardia announced that the FDA confirmed the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System, supporting a follow-on De Novo pre-submission for approval.
Source:Aug 21, 2026, 00:00 UTC
BioCardia, Inc. received a notice from NASDAQ on August 19, 2026, stating that the company no longer complies with the minimum bid price requirement under Rule 5550(a)(2), and has until February 16, 2027, to regain compliance.
Aug 13, 2026, 04:47 UTC
BioCardia, Inc. held its Q2 2026 earnings call on August 12, 2026, to discuss financial results and business updates.
Source:Jun 8, 2026, 12:00 UTC
BioCardia completed a $4.4 million financing to extend its cash runway.
Source: